Abstract: The disclosure provides polypeptides comprising an engineered p27, or a fragment thereof such polypeptides may be used to form trimeric protein complexes with a cyclin-dependent kinase 4 (Cdk4) (or a variant thereof) or Cdk6 (or a variant thereof), and a cyclin D (CycD) or a variant thereof.

Abstract: The present invention is a cannabidiol oral dosage form including predominantly or exclusively bacterially fermented hemp pomace, compounded as a tablet or formulated within a capsule generally without the addition of synthetic excipients, fillers or other additives, not including the inevitable presence of some moisture. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG, etc.) in a ratio of 60:1 up to 120:1 to hallucinogenic cannabinoids (THC).

Abstract: The present invention is a cannabidiol oral dosage form including predominantly or exclusively bacterially fermented hemp pomace, compounded as a tablet or formulated within a capsule generally without the addition of synthetic excipients, fillers or other additives, not including the inevitable presence of some moisture. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG, etc.) in a ratio of 60:1 up to 120:1 to hallucinogenic cannabinoids (THC).

Abstract: The disclosure provides polypeptides comprising an engineered p27, or a fragment thereof such polypeptides may be used to form trimeric protein complexes with a cyclin-dependent kinase 4 (Cdk4) (or a variant thereof) or Cdk6 (or a variant thereof), and a cyclin D (CycD) or a variant thereof.

Abstract: The present invention is a cannabidiol oral dosage form including predominantly or exclusively bacterially fermented hemp pomace, compounded as a tablet or formulated within a capsule generally without the addition of synthetic excipients, fillers or other additives, not including the inevitable presence of some moisture. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG, etc.) in a ratio of 60:1 up to 120:1 to hallucinogenic cannabinoids (THC).

Abstract: The disclosure provides polypeptides comprising an engineered p27, or a fragment thereof. Such polypeptides may be used to form trimeric protein complexes with a cyclin-dependent kinase 4 (Cdk4) (or a variant thereof) or Cdk6 (or a variant thereof), and a cyclin D (CycD) or a variant thereof.

Abstract: The present invention is a cannabidiol oral dosage form including predominantly or exclusively hemp pomace, compounded as a tablet or formulated within a capsule without the addition of synthetic excipients, fillers or other additives, not including the inevitable presence of some moisture and the optional presence of fungal or bacterial probiotics introduced prior to or during dosage form manufacturing, and with or without fermentation of the hemp pomace prior to the dosage form manufacturing process. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG) in a ratio of 30:1 up to 120:1 to hallucinogenic cannabinoids (THC).

Abstract: The present invention is a cannabidiol oral dosage form including predominantly or exclusively bacterially fermented hemp pomace, compounded as a tablet or formulated within a capsule generally without the addition of synthetic excipients, fillers or other additives, not including the inevitable presence of some moisture. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG, etc.) in a ratio of 60:1 up to 120:1 to hallucinogenic cannabinoids (THC).

Abstract: Cyclic peptides that inhibit MDM2 or MDM2 and MDM4, pharmaceutical compositions containing these cyclic peptides, and methods of using these cyclic peptides for inhibiting MDM2 or MDM2 and MDM4 are described herein.

Abstract: The present invention is a cannabidiol oral dosage form including predominantly or exclusively hemp pomace that has been co-fermented with a complex fungi, compounded as a tablet or formulated within a capsule. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of at least one part soluble dietary fiber to 30 parts insoluble dietary fiber, and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG) in a ratio of 60:1 up to 120:1 to hallucinogenic cannabinoids (THC).

Abstract: The present invention is a method of preparing and potentiating functional foods and, in particular, herbs, by subjecting the food or herb to specific method steps, either a particular three- or four- step potentiating process or a specific infusion/fermentation potentiating technique, for which in some embodiments the fermentation is optional.

Abstract: A process for growing mycelium with cannabis, by designing and filling a spawn bag with medium containing cannabis, water and optional grain, followed by inoculating and maturing mycelium spawn to grow and harvest mushrooms with optional drying thereafter.

Abstract: The invention is a method for enhanced growth of mycelium in culture including the key steps of seed blend choice from among corn, rice, quinoa, chia, canihua, cumin and flax seed, germinating the seed blend prior to inoculating the mycelium starter, and conducting the mushroom cultivation with water and particular transmissions of sound and particularly colored light. Mushrooms grown by such a method not only mature in 13-15 days rather than 21 days, but have an enhanced nutritional and medicinal profile along with absence of unwanted organism contaminants whose unwanted overgrowth occurs during days 16-21 (or days 16-28) of typical mushroom culture.

Abstract: The invention is a nutritional composition in unit dosage form for oral administration to an animal or human, which includes at least one ingredient from each of six biological Kingdoms selected from the group consisting of animals, plants, fungi, bacteria, protist and archaea. Each ingredient is co-admixed with every other said ingredient without further addition of synthetic excipients or fillers, and is typically formulated in dried powder form as a drink mix, food or beverage additive or as the fill for hard or soft capsules or other dosage forms including tablets (the compositions of the invention can generally be tableted without addition of ingredients beyond the nutrients themselves).

Abstract: The invention is a nutritional composition in unit dosage form for oral administration to an animal or human, which includes at least one ingredient from each of six biological Kingdoms selected from the group consisting of animals, plants, fungi, bacteria, protist and archaea. Each ingredient is co-admixed with every other said ingredient without further addition of synthetic excipients or fillers, and is typically formulated in dried powder form as a drink mix, food or beverage additive or as the fill for hard or soft capsules or other dosage forms including tablets (the compositions of the invention can generally be tableted without addition of ingredients beyond the nutrients themselves).

Abstract: The invention is a nutraceutical composition which is admixed to contain two or more forms of botanicals selected from the group consisting of activated botanical, native botanical, aerial botanical and root botanical. For Cannabis/hemp forms according to the invention, the nutraceutical composition may contain one or more of native root Cannabis/hemp, activated root Cannabis/hemp, native “aerial” (above ground) portions of Cannabis/hemp and/or activated “aerial” portions of Cannabis/hemp.

Abstract: The present invention is a pharmaceutical cocktail of at least two botanical leaves (or extracts therefrom) specifically harvested from trees or plants that bear edible fruit, and including no other leaves of any kind. The combination of leaves from multiple families or at the very least genera provides the greatest variety of phytochemicals. A prime nonlimiting example is a combination of leaves such as Soursop (Annonaceae Family, Annona Genus), Blackberry (Rosaceae Family, Rubus Genus), Lemon (Rutaceae Family, Citrus Genus). In an embodiment of the invention, at least twelve leaf types (from at least different species if not higher biological categories) are admixed into such an active agent admixture—again, with each leaf type coming from a plant or tree that bears edible fruit. The present compositions and extracts always contain a minimum of 25 distinct active phytochemicals, which together provide nutraceutical and pharmaceutical action as to animals and humans.

Abstract: The present invention is a novel and enhanced co-fermentation product of hemp and cannabis, in which 1 part by weight shredded or divided hemp stems, leaves and flowers are admixed into a slurry with at least one part by weight up to two parts by weight water and the slurry is sterilized prior to inoculation with solid or liquid mycelium culture. After inoculation, fermentation takes place at 66-70 degrees F. for 14-28 days, followed by drying of the fermented admixture at 110-165 degrees F. for 24-48 hours, prior to co-minuting or powdering the dried end product for incorporation in oral dosage forms such as pressed tablets, manufactured capsules or powder or as an ingredient in functional foods. By following these method steps including the initial creation of aqueous hemp slurry with the prescribed ratio ranges of water, both hemp and mushroom component conversions occur to an unexpected degree.

Abstract: The present invention is a cannabidiol oral dosage form including predominantly or exclusively bacterially fermented hemp pomace, compounded as a tablet or formulated within a capsule generally without the addition of synthetic excipients, fillers or other additives, not including the inevitable presence of some moisture. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG, etc.) in a ratio of 60:1 up to 120:1 to hallucinogenic cannabinoids (THC).

Abstract: The present invention is a novel and enhanced co-fermentation product of hemp and Cannabis, in which 1 part shredded or divided hemp stems, leaves and flowers are admixed into a slurry with 2 parts water and the slurry is sterilized prior to inoculation with solid or liquid mycelium culture. After inoculation, fermentation takes place at 66-70 degrees F. for 14-28 days, followed by drying of the fermented admixture at 110-165 degrees F. for 24-48 hours, prior to co-minuting or powdering the dried end product for incorporation in oral dosage forms such as pressed tablets, manufactured capsules or powder or as an ingredient in functional foods. By following these method steps including the initial creation of the 2:1 aqueous:hemp slurry, both hemp and mushroom component conversions occur to an unexpected degree.